EXTH-91. GALECTIN-3 INHIBITOR PAIRED WITH FOCAL LOW-INTENSITY NONINVASIVE TDCS CAN ACHIEVE MAXIMAL THERAPEUTIC BENEFIT IN CLINICALLY RELEVANT MENINGIOMA MOUSE MODELS

Atypical and anaplastic meningiomas (WHO Grade 2 and WHO Grade 3 respectively) represent a subgroup of meningiomas that tend to have higher rates of recurrence with associated’s higher morbidity and mortality than the more common WHO Grade 1 meningiomas. Our laboratory data demonstrated that galecti...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2022-11, Vol.24 (Supplement_7), p.vii230-vii230
Hauptverfasser:	Das, Arabinda, McDonald, Daniel G, Yazdani, Milad, Stephenson, Connor, Mehrotra, Shikhar, Welsh, Cynthia A, Infinger, Libby Kosnik, Vandergrift, William A, Varma, Abhay K, Patel, Sunil J, Giglio, Pierre, Zukas, Alicia, Cachia, David, Lindhorst, Scott M
Format:	Artikel
Sprache:	eng
Schlagworte:	Preclinical Experimental Therapeutics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!